Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Announces Presentations at the American Society for Experimental Neurotherapeutics (ASENT) 2020 Annual MeetingRead More
Zynerba Pharmaceuticals Announces Achievement of Patient Screening Target for Pivotal Trial of Zygel™ in Fragile X SyndromeRead More
Zynerba Pharmaceuticals Announces that Enrollment is Nearing Completion in Pivotal CONNECT-FX Trial in Fragile X SyndromeRead More
Zynerba Pharmaceuticals Announces Achievement of Enrollment Target in Phase 2 Trial of Zygel™ in Autism Spectrum DisorderRead More